CommercialCoverageMedium impact
11.08.17k, Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toenails
Independence Blue Cross·Podiatry, Dermatology·Medical Policy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Summary
Policy 11.08.17k was reissued effective April 2, 2025, addressing coverage and billing guidelines for debridement of mycotic and symptomatic non-mycotic hypertrophic toenails. The billing team must review this reissued policy to identify any changes from the previous version and update billing workflows, coding guidance, and coverage determinations accordingly.
Action Required
By April 16, 2025: Billing team must obtain the full policy text from the source URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=04&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-11-08-17k) to identify specific CPT/HCPCS codes, coverage criteria, and any prior authorization requirements. Update billing system edits, encounter forms, and provider documentation templates to reflect the reissued guidance. Flag any claims submitted between April 2-16, 2025 for review to ensure compliance with new requirements. Communicate changes to providers and front-desk staff. Failure to align with this reissued policy may result in claim denials or overpayment recovery.